市场调查报告书
商品编码
1532127
临床试验成像的全球市场的评估:各类服务,各种模式,各治疗领域,各终端用户,各地区,机会,预测(2017年~2031年)Clinical Trial Imaging Market Assessment, By Services, By Modality, By Therapeutic Area, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球临床试验影像市场规模预计将从 2023 年的 13.5 亿美元增至 2031 年的 25 亿美元,预计 2024-2031 年的复合年增长率为 8.01%。该市场受到研发费用增加、医学影像公司扩张以及临床研究组织(CRO)数量增加等因素的推动。
医学影像对于先进生命科学设备和套件的开发至关重要。儘管医学影像市场不断变化,但生物技术和製药行业却表现出持续成长。这主要是由于对医学影像公司的投资和併购增加,包括采用创新影像技术来促进医疗设备的临床试验。技术进步极大地改善了临床试验影像资料的收集、解释和提交。基于技术的成像,尤其是影像分析软体,为临床研究提供了多种好处,包括均匀性、资料品质、灵活性和合规性。例如,影像分析软体可以透过评估拍摄影像的时间点来指导和监督阅片医师。此外,随着处理能力的提高,成像技术的使用也在增加,并且在临床试验中的影像使用预计将加速。定量成像生物标记联盟 (QIBA) 计画开发了标准化方法和成像流程,以在临床试验中实现科学且精确定义的结果。
2024 年5 月,Parexel International Corporation(Calyx Medical Imaging)宣布启动Iovance Biotherapeutic 的Amtagvi (lifileucel) 的关键II 期临床试验,这是一种针对现有一线治疗失败的转移性黑色素瘤患者的细胞疗法。 Calyx 支持临床试验的诊断影像部分的开发和实施。因此,60个研究中心能够根据影像评估方法收集患者的CT、磁振造影(MRI)、正子断层扫描(PET)和皮肤图。
研发费用增加
不断增加的研发(R&D)费用是临床试验影像市场成长的主要动力。随着製药和生物技术公司增加研发投资以寻找新药和治疗方法,需要一个有效的临床试验系统。随着这些公司在研发上投入更多资金,对临床试验影像服务的需求也随之增加,因为影像对于确定新药的有效性和安全性至关重要。 Qureight Ltd. 宣布完成价值 850 万美元的 A 轮融资,透过临床试验成像推进新药开发的成像。 Qureight Ltd. 的数位基础设施公司管理各种医疗数据以进行全面测试。 Qureight Ltd. 透过与英国 NHS 签订的数据协议拥有独特的医疗保健访问权限,使我们能够直接从医院和临床研究组织 (CRO) 即时收集 CT 扫描、生物标誌物和其他临床试验终点。
医疗影像公司的扩张推动市场成长
由于对改善诊断能力和技术进步的需求不断增加,医学影像公司持续成长。一个显着的发展是便携式手持成像技术的生产,例如袖珍超音波机,可以在各种模式和成像位置提供护理点诊断。此外,将人工智慧和机器学习融入诊断成像系统可以提高诊断准确性和工作流程效率。西门子 Healthineers 和 GE Healthcare 等公司正在推出便携式 MRI 系统和自动 X 光扫描仪等突破性技术,以提高可及性并加快操作速度。 2023 年 12 月,GE Healthcare Technologies Inc. 在美国放射学会科学会议和年会 (RSNA 2023) 上宣布推出一款基于人工智慧的新型 MRI 机器。
本报告提供全球临床试验成像市场相关调查分析,提供市场规模与预测,市场动态,主要企业的形势及预测等资讯。
Global clinical trial imaging market is projected to witness a CAGR of 8.01% during the forecast period 2024-2031, growing from USD 1.35 billion in 2023 to USD 2.50 billion in 2031. The global clinical trial imaging market is being driven by factors such as growing expenditures in research and development, expansion of medical imaging companies, and increasing number of Clinical Research Organizations (CROs).
Medical imaging is essential for the development of advanced life science devices and kits. Despite the ever-changing nature of the medical imaging market, the biotechnology and pharmaceutical industries are experiencing consistent growth. This is mostly owing to increased investment in medical imaging firms, and mergers and acquisitions including the adoption of innovative imaging technology to facilitate clinical trials for medical devices. Technological advancements are significantly improving the collection, interpretation, and submission of clinical trial imaging data. Technology-based imaging, particularly image analysis software, brings several advantages to clinical research, including uniformity, data quality, flexibility, and compliance. For instance, image analysis software may be used to guide and supervise a reader by evaluating imaging points in time. Furthermore, the increasing use of imaging technologies, along with improved processing power, is projected to accelerate the use of imaging in clinical trials. The Quantitative Imaging Biomarkers Alliance (QIBA) program has developed standardized methodologies and imaging processes to achieve scientifically and precisely defined outcomes in clinical studies.
In May 2024, Parexel International Corporation (Calyx Medical Imaging) announced its involvement in the pivotal phase II clinical study of Iovance Biotherapeutic's Amtagvi (lifileucel), a cell therapy for people with metastatic melanoma who have failed existing front-line treatments. Calyx helped develop and implement the imaging components of trials. Thus, 60 investigation sites were able to collect patient CT, magnetic resonance imaging (MRI), positron emission tomography (PET), and skin photography pictures in accordance with the image review methodology.
Growing Expenditures in Research and Development
Rising research and development (R&D) expenditures are a major driver for the growth of the clinical trial imaging market. Pharmaceutical and biotechnology businesses are growing their investment in R&D in search of new drugs and cures, necessitating effective clinical trial systems. As these corporations devote more money to R&D, the need for clinical trial imaging services increases, as imaging is critical in determining the efficacy and safety of new medicines. Qureight Ltd. announced their Series A round completion worth USD 8.5 million for expediting drug development imaging through clinical trial imaging. Qureight Ltd.'s digital infrastructure houses curates a variety of medical data for thorough examination. Qureight Ltd. has unique healthcare access through NHS England data contracts, allowing it to collect CT scans, biomarkers, and other trial endpoints directly from hospitals or clinical research organizations (CROs) in real time.
Expansion of Medical Imaging Companies to Drive Market Growth
Medical imaging firms are growing due to increased demand for enhanced diagnostic capabilities and technical advancements. Notable developments include manufacturing of portable and handheld imaging technologies, such as pocket-sized ultrasound devices, which provide point-of-care diagnostics in different modalities and imaging positions. Additionally, incorporating artificial intelligence (AI) and machine learning into imaging systems improves diagnosis accuracy and workflow efficiency. Companies such as Siemens Healthineers and GE Healthcare are introducing revolutionary technologies such as portable MRI systems and automated x-ray scanners to increase accessibility and accelerate operations. In December 2023, GE Healthcare Technologies Inc. announced the launch of its new AI-based MRI machine at the Radiological Society of America Scientific Sessions and Annual Meetings (RSNA 2023).
CT Scans Dominate the Global Clinical Trial Imaging Market Share
Computed tomography (CT) devices have been frequently used in clinical trial imaging due to their ability to produce detailed images of internal organs. CT scans use X-rays and computer processing to generate comprehensive cross-sectional digital images of the body, allowing clinicians and researchers to detect and quantify changes in tissues and organs over time. CT scans are secure and convenient for patients and researchers. Furthermore, researchers prefer CT scans as they can generate large volumes of data in a short period of time, which is useful for collecting and analyzing data from several patients to detect trends and patterns. The fast-track coronary artery bypass grafting (CABG) study, was led by the University's CORRIB research center for advanced imaging and core lab. Heart surgeons planned and performed CABG using non-invasive cardiac-CT scan images with the help of HeartFlow's AI-powered blood flow analysis, the doctors were able to identify problems in patient's coronary arteries.
Oncology to Account Dominant Market Share
Oncology is the leading segment amongst different types of therapeutic areas. The factors such as high prevalence of cancer cases and constant need for new and innovative therapies to treat various cancer types are expected to fuel market growth. Oncology trials often involve complex imaging requirements due to the need to assess tumor size, treatment responses, and disease progression. Various imaging modalities, such as CT scans, MRI, PET scans, and others, are used to evaluate the effectiveness of cancer treatments. This complexity results in a larger share of the market being dedicated to oncology.
Future Market Scenario (2024-2031F)
Future clinical trials will be increasingly employed with multi-modal imaging techniques, combining various imaging modalities such as MRI, CT, and PET. This approach will offer a comprehensive view of anatomical and physiological processes, facilitating better correlation of findings and improving the overall understanding of pathologies.
The use of wearable devices will provide continuous, real-time health data from trial participants. The technology aims to enhance patient engagement and reduce the burden of participation by allowing remote monitoring, thus making clinical trials more accessible and patient centric.
AI is set to revolutionize clinical trial imaging by enhancing diagnostic accuracy and efficiency. AI algorithms will improve image quality, reduce scan times, and automate tasks such as image interpretation and report generation. It will allow radiologists to focus on more complex cases while ensuring timely and precise disease detection.
The trend towards decentralized clinical trials will continue, leveraging technology to conduct trials remotely. It will involve partnerships with end-to-end solution providers who can manage imaging logistics, data harmonization, and secure analysis, ultimately enhancing trial efficiency and participant experience.
Key Players Landscape and Outlook
Several medical imaging companies and clinical research organizations are growing in the global clinical trial imaging market by planning and adopting new strategies. New agreements, contracts, mergers and acquisitions, investments, and partnerships, along with major strategic initiatives through which companies are increasing their market shares.
Pie Medical Imaging Inc., a global leader in cardiac imaging, announced in June 2024 its enrollment in FASTIII, a multi-center randomized clinical trial. The trial is investigating the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures. The vFFR can determine whether a coronary artery narrowing is functionally substantial and requires revascularization.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.